JP2024523166A5 - - Google Patents
Info
- Publication number
- JP2024523166A5 JP2024523166A5 JP2023574290A JP2023574290A JP2024523166A5 JP 2024523166 A5 JP2024523166 A5 JP 2024523166A5 JP 2023574290 A JP2023574290 A JP 2023574290A JP 2023574290 A JP2023574290 A JP 2023574290A JP 2024523166 A5 JP2024523166 A5 JP 2024523166A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- antigen
- expression vector
- seq
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163210787P | 2021-06-15 | 2021-06-15 | |
| US63/210,787 | 2021-06-15 | ||
| PCT/US2022/033625 WO2022266219A1 (en) | 2021-06-15 | 2022-06-15 | Heterodimeric antibodies that bind claudin18.2 and cd3 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024523166A JP2024523166A (ja) | 2024-06-28 |
| JP2024523166A5 true JP2024523166A5 (https=) | 2025-06-23 |
Family
ID=82608587
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023574290A Pending JP2024523166A (ja) | 2021-06-15 | 2022-06-15 | クローディン１８．２及びｃｄ３に結合するヘテロ二量体抗体 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20240247062A1 (https=) |
| EP (1) | EP4355784A1 (https=) |
| JP (1) | JP2024523166A (https=) |
| WO (1) | WO2022266219A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025122927A1 (en) * | 2023-12-06 | 2025-06-12 | Integral Molecular, Inc. | Antibodies directed to claudin 18.2, including bispecific formats thereof |
| WO2026055669A2 (en) * | 2024-09-09 | 2026-03-12 | Xencor, Inc. | Anti-tl1a x anti-il23 antibodies |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US459007A (en) | 1891-09-08 | Porte | ||
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US20060134105A1 (en) | 2004-10-21 | 2006-06-22 | Xencor, Inc. | IgG immunoglobulin variants with optimized effector function |
| AU2004297616B2 (en) | 2003-12-04 | 2008-12-18 | Xencor, Inc. | Methods of generating variant proteins with increased host string content and compositions thereof |
| US8367805B2 (en) | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| EP1790664A1 (en) | 2005-11-24 | 2007-05-30 | Ganymed Pharmaceuticals AG | Monoclonal antibodies against claudin-18 for treatment of cancer |
| ES2758994T3 (es) | 2010-11-05 | 2020-05-07 | Zymeworks Inc | Diseño anticuerpo heterodimérico estable con mutaciones en el dominio Fc |
| JP6499079B2 (ja) | 2012-11-13 | 2019-04-10 | バイオエヌテック アーゲーＢｉｏＮＴｅｃｈ ＡＧ | クローディンを発現するガン疾患を処置するための剤 |
| WO2014075697A1 (en) * | 2012-11-13 | 2014-05-22 | Biontech Ag | Agents for treatment of claudin expressing cancer diseases |
| KR102211837B1 (ko) | 2013-01-14 | 2021-02-03 | 젠코어 인코포레이티드 | 신규한 이형이량체 단백질 |
| JP6594855B2 (ja) | 2013-03-15 | 2019-10-23 | ゼンコア インコーポレイテッド | ヘテロ二量体タンパク質 |
| EP3699195A3 (en) | 2014-03-28 | 2020-11-04 | Xencor, Inc. | Bispecific antibodies that bind to cd38 and cd3 |
| CN109715663B (zh) * | 2016-06-28 | 2022-11-25 | Xencor股份有限公司 | 结合生长抑素受体2的异源二聚抗体 |
| WO2018054484A1 (en) * | 2016-09-23 | 2018-03-29 | Biontech Ag | Bispecific trivalent antibodies binding to claudin 6 or claudin18.2 and cd3 for treatment of claudin expressing cancer diseases |
| CA3096052A1 (en) * | 2018-04-04 | 2019-10-10 | Xencor, Inc. | Heterodimeric antibodies that bind fibroblast activation protein |
| WO2019242505A1 (zh) * | 2018-06-17 | 2019-12-26 | 上海健信生物医药科技有限公司 | 靶向cldn18.2的抗体、双特异性抗体、adc和car及其应用 |
| WO2020025792A1 (en) * | 2018-08-03 | 2020-02-06 | Amgen Research (Munich) Gmbh | Antibody constructs for cldn18.2 and cd3 |
| KR102773187B1 (ko) * | 2019-07-12 | 2025-02-27 | 퓨쳐진 바이오파머쓰티컬 (베이징) 코., 엘티디. | Cldn18.2 항체 및 이의 용도 |
| KR102777693B1 (ko) * | 2019-07-17 | 2025-03-07 | 더 리전트 오브 더 유니버시티 오브 캘리포니아 | Claudin18 항체 및 암 치료 방법 |
| US20230030674A1 (en) * | 2019-12-06 | 2023-02-02 | Sotio Biotech A.S. | Humanized cldn18.2 antibodies |
-
2022
- 2022-06-15 WO PCT/US2022/033625 patent/WO2022266219A1/en not_active Ceased
- 2022-06-15 EP EP22743977.5A patent/EP4355784A1/en active Pending
- 2022-06-15 US US18/564,994 patent/US20240247062A1/en active Pending
- 2022-06-15 JP JP2023574290A patent/JP2024523166A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023538891A5 (https=) | ||
| JP2025508827A5 (https=) | ||
| JP2021151253A5 (https=) | ||
| JP2022503959A5 (https=) | ||
| AR120511A2 (es) | Producción de proteínas heteromultiméricas | |
| JP2021019642A5 (https=) | ||
| JP2024523166A5 (https=) | ||
| JP2005516613A5 (https=) | ||
| JP2025066711A5 (https=) | ||
| JP2014506790A5 (https=) | ||
| DK1716178T3 (da) | Mindre immunogene bindingsmolekyler | |
| RU2012122173A (ru) | Варианты альбумина | |
| JPWO2021100640A5 (https=) | ||
| JP2016104045A5 (https=) | ||
| JP2018520654A5 (https=) | ||
| RU2013140685A (ru) | ВАРИАНТЫ Fc, СПОСОБЫ ИХ ПОЛУЧЕНИЯ | |
| JP2010539926A5 (https=) | ||
| CL2008002349A1 (es) | Molecula de anticuerpo que se une a cd37 humano; molecula de adn que la codifica; vector de expresion y celula huesped; metodo para producir dicho anticuerpo; composicion farmaceutica que la comprende; método in vitro para suprimir células b que expresan cd37 en una población de células. | |
| CA2532966A1 (en) | Igm production by transformed cells and methods for quantifying said igm production | |
| JP2025090679A5 (https=) | ||
| JP2004041218A5 (https=) | ||
| RU2011154363A (ru) | Комбинации клад rrgb пневмококков | |
| JP2023171909A5 (https=) | ||
| EA201400192A1 (ru) | Клетка, ферментирующая пентозы | |
| JP2004528803A5 (https=) |